Item 9 Labs(OTC) INLB

Item 9 Labs Corp. is a comprehensive cannabis company based in the United States, specializing in both vertical integration of cannabis operations and the franchising of dispensaries. The firm produces a diverse range of cannabis products, including raw flower, concentrates, and distillates, which are supplied to consumers in Arizona through licensed retail dispensaries.

Products and Services

• Production of cannabis products including raw flower and concentrates
• Franchising of medical and adult-use cannabis dispensaries under the Unity Rd brand
• Development of cannabis-related technologies and hardware

Growth Outlook

• Revenue increased to $5,022,375 in Q3 2023, showing strong market demand
• Gross profit margin improved to 56.1% in Q3 2023, indicating operational efficiency
• Expansion of dispensary franchises expected to drive future revenue growth

Financial Highlights

• Net income for Q3 2023 was -$5,911,194, reflecting ongoing investment in growth
• Operating expenses totaled $5,784,861 in Q3 2023, highlighting significant operational scale
• Cash and cash equivalents increased to $183,429 by the end of Q3 2023

Item 9 Labs Corp. operates in the rapidly growing cannabis industry, which has seen increasing consumer acceptance and regulatory support. The company's focus on both production and franchising positions it well to capitalize on market opportunities. Recent financial performance indicates a commitment to growth, despite current net losses, as the company invests in expanding its operational capabilities and market presence. The improvement in gross profit margins suggests that operational efficiencies are being realized, which could enhance profitability in the future. As the cannabis market continues to evolve, Item 9 Labs Corp. is poised to leverage its integrated business model for sustained growth.